aHUS Observational Long Term Follow-Up (LTFU)

Alexion Pharmaceuticals

Status: Terminated

Conditions: Atypical Hemolytic Uremic Syndrome

Study type: Observational

Funder types: Industry

Identifiers

NCT01522170

C11-003

Details and patient eligibility

About

There is growing but limited information on the long term clinical status of aHUS patients who have previously received or are continuing to receive treatment with eculizumab. This study is designed to collect clinical data that will provide insight into the long-term outcomes of patients with aHUS.

Enrollment: 94 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• aHUS patients who participated in any one of the aHUS-eculizumab clinical studies.
• aHUS patients or legal representative who are able and willing to given written informed consent for their study information to be collected and retained in a database.

Exclusion criteria

• Not applicable.